Cancer cell, Vol. 34, Issue 5, Pages 792-806.e5, 2018

PMID: 30449325

Deregulated HER2 is a target of many approved cancer drugs. We analyzed 111,176 patient tumors and identified recurrent mutations in HER2 transmembrane domain (TMD) and juxtamembrane domain (JMD) that include G660D, R678Q, E693K, and Q709L.

Read More

  https://www.ncbi.nlm.nih.gov/pubmed/30449325